The importance of new therapeutic targets for neutrophil inflammation regulation in case of broncho-obstructive pulmonary diseases
- Authors: Kupaev V.I.1, Shagurov A.S.1, Limareva L.V.1, Tkachenko K.M.2, Kuritsyna A.P.1
-
Affiliations:
- Samara State Medical University of the Ministry of Healthcare of Russia
- V.D. Seredavin Samara Regional Clinical Hospital
- Issue: Vol 10, No 6 (2024)
- Pages: 15-22
- Section: ORIGINAL STUDIES
- URL: https://journals.rcsi.science/2412-4036/article/view/264890
- DOI: https://doi.org/10.18565/therapy.2024.6.15-22
- ID: 264890
Cite item
Open Access
Access granted
Subscription Access
Abstract
Search for effective therapeutic targets to control neutrophilic inflammation in chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA) is an urgent task of the research.
The aim: to evaluate the importance of P-selectin and siglec-9 in regulation of neutrophilic inflammation taking place in broncho-obstructive pulmonary diseases.
Material and methods. A study of patients suffering from broncho-obstructive diseases was made in 3 groups: group I – patients with BA of mixed genesis (n = 44), group II – patients with COPD (n = 36), control group (n = 30). Clinical, spirometric parameters and immunological markers were assessed using enzyme immunoassay (P-selectin, siglec-9, interleukins 4 and 8, tumor necrosis factor-alpha, interferon gamma).
Results. Median values of P-selectin in case of mixed BA and COPD were at the level of 60.48 (41.48– 147.17) and 91.17 (53.72–135.60) pg/ml, respectively, that had statistically significant differences from the control group, where this index was 47.67 (40.34–65.98) pg/ml. The level of P-selectin in BA and COPD groups did not differ significantly. Siglec-9 value was very low in all groups, but 15 patients were positive for this marker. Mainly they were patients with mixed BA (n = 11). Multivariate cluster analysis, including the main phenotypic signs of diseases (age, smoking status, body mass index) and levels of P-selectin, Siglec-9, interleukin 4, tumor necrosis factor-alpha, interferon gamma, showed that the most consistent features for clustering were smoking, age, body mass index, concentrations of P-selectin, interferon gamma and interleukin 4.
Conclusion. The role of P-selectin and siglec-9 in neutrophilic inflammation regulation in patients with chronic broncho-obstructive pulmonary diseases was ambiguously estimated in the current study. In our opinion, the most convincing promising therapeutic target for controlling neutrophilic inflammation may be P-selectin.
Full Text
##article.viewOnOriginalSite##About the authors
Vitaly I. Kupaev
Samara State Medical University of the Ministry of Healthcare of Russia
Author for correspondence.
Email: vk1964sam@rambler.ru
ORCID iD: 0000-0003-2639-0003
MD, Dr. Sci. (Medicine), professor, head of the Department of family medicine with a course of telemedicine technologies
Russian Federation, SamaraAlexander S. Shagurov
Samara State Medical University of the Ministry of Healthcare of Russia
Email: ashagurov@yandex.ru
ORCID iD: 0000-0001-6508-3095
MD, postgraduate student of the Department of family medicine with a course in telemedicine technologies
Russian Federation, SamaraLarisa V. Limareva
Samara State Medical University of the Ministry of Healthcare of Russia
Email: l.v.limareva@samsmu.ru
ORCID iD: 0000-0003-4529-5896
MD, Dr. Sci. (Biology), associate professor, professor of the Department of general and clinical microbiology, immunology and allergology
Russian Federation, SamaraKsenia M. Tkachenko
V.D. Seredavin Samara Regional Clinical Hospital
Email: Ksenya2009@list.ru
ORCID iD: 0009-0006-7433-6609
MD, pulmonologist
Russian Federation, SamaraAnna P. Kuritsyna
Samara State Medical University of the Ministry of Healthcare of Russia
Email: a.p.kuricyna@samsmu.ru
ORCID iD: 0000-0003-2799-7632
MD, specialist at the Department of human metagenomics of Scientific and Educational Professional Center for Genetic and Laboratory Technologies
Russian Federation, SamaraReferences
- Mitra A.K., Bhuiyan A.R., Jones E.A. Association and risk factors for obstructive sleep apnea and cardiovascular diseases: A systematic review. Diseases. 2021; 9(4): 88. https://doi.org/10.3390/diseases9040088. PMID: 34940026. PMCID: PMC8700568.
- McCarthy D.E., Piasecki T.M., Jorenby D.E. et al. A multi-level analysis of non-significant counseling effects in a randomized smoking cessation trial. Addiction. 2010; 105(12): 2195–208. https://doi.org/10.1111/j.1360-0443.2010.03089.x. PMID: 20840173. PMCID: PMC2975757.
- Derella C.C., Tingen M.S., Blanks A. et al. Smoking cessation reduces systemic inflammation and circulating endothelin-1. Sci Rep. 2021; 11(1): 24122. https://doi.org/10.1038/s41598-021-03476-5. PMID: 34916543. PMCID: PMC8677816.
- Cavaillès A., Brinchault-Rabin G., Dixmier A. et al. Comorbidities of COPD. Eur Respir Rev. 2013; 22(130): 454–75. https://doi.org/10.1183/09059180.00008612. PMID: 24293462. PMCID: PMC9639181.
- Messner B., Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014; 34(3): 509–15. https://doi.org/10.1161/ATVBAHA.113.300156. PMID: 24554606.
- Avdeev S., Aisanov Z., Arkhipov V. et al. Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. Int J Chron Obstruct Pulmon Dis. 2019: 14: 1267–80. https://doi.org/10.2147/COPD.S207775. PMID: 31354256. PMCID: PMC6572750.
- Zeng Z., Li M., Wang M. et al. Increased expression of Siglec-9 in chronic obstructive pulmonary disease. Sci Rep. 2017; 7(1): 10116. https://doi.org/10.1038/s41598-017-09120-5. PMID: 28860481. PMCID: PMC5579055.
- Chen Z., Bai F.-F., Han L. et al. Targeting neutrophils in severe asthma via Siglec-9. Int Arch Allergy Immunol. 2018; 175(1–2): 5–15. https://doi.org/10.1159/000484873. PMID: 29306942.
- Chen Z., Xu S.-L., Ge L.-Y. et al. Sialic acid-binding immunoglobulin-like lectin 9 as a potential therapeutic target for chronic obstructive pulmonary disease. Chin Med J (Engl). 2021; 134(7): 757–64. https://doi.org/10.1097/CM9.0000000000001381. PMID: 33595976. PMCID: PMC8104259.
- Aleva F.E., Temba G., de Mast Q. et al. Increased platelet-monocyte interaction in stable COPD in the absence of platelet hyper-reactivity. Respiration. 2018; 95(1): 35–43. https://doi.org/10.1159/000480457. PMID: 29020675.
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2023. Updated July 2023. URL: http://www.ginasthma.org (date of access – 17.06.2024).
- Venkatesan P. GOLD COPD report: 2024 update. Lancet Respir Med. 2024; 12(1): 15–16. https://doi.org/10.1016/S2213-2600(23)00461-7. PMID: 38061380.
- Schumacher A., Liebers U., John M. et al. P-selectin glycoprotein ligand-1 (PSGL-1) is up-regulated on leucocytes from patients with chronic obstructive pulmonary disease. Clin Exp Immunol. 2005; 142(2): 370–76. https://doi.org/10.1111/j.1365-2249.2005.02920.x. PMID: 16232226. PMCID: PMC1809501.
Supplementary files
